EXEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-18), Exelixis's share price is $22.49. Exelixis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.52. Hence, Exelixis's Price-to-Free-Cash-Flow Ratio for today is 43.00.
The historical rank and industry rank for Exelixis's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Exelixis's highest Price-to-Free-Cash-Flow Ratio was 68.15. The lowest was 9.28. And the median was 25.48.
Exelixis's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.52.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Exelixis was -23.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -1.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -16.10% per year.
During the past 13 years, Exelixis's highest 3-Year average Free Cash Flow per Share Growth Rate was 40.10% per year. The lowest was -73.30% per year. And the median was -1.90% per year.
The historical data trend for Exelixis's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exelixis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Exelixis's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Exelixis's Price-to-Free-Cash-Flow falls into.
Exelixis's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 22.49 | / | 0.523 | |
= | 43.00 |
Exelixis's Share Price of today is $22.49.
Exelixis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Exelixis (NAS:EXEL) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Exelixis's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick J. Haley | officer: Sr. Vice President, Commercial | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Jeffrey Hessekiel | officer: EVP and General Counsel | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
David Edward Johnson | director | 590 MADISON AVENUE, NEW YORK NY 10022 |
Dana Aftab | officer: CSO/EVP Disc & Trans Research | EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Amy C. Peterson | officer: EVP Prod Dev & Med Aff & CMO | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Christopher J. Senner | officer: EVP and CFO | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Bob Oliver | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Caligan Partners Lp | director, other: See Remarks | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Jack L Wyszomierski | director | SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000 |
Alan M Garber | director | 3355 MILTON COURT, MOUNTAIN VIEW CA 94040 |
Carl B Feldbaum | director | C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511 |
Peter Lamb | officer: EVP, Discovery Research & CSO | PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511 |
George Poste | director | 515 GALVESTON DR, REDWOOD CITY CA 94063 |
Lance Willsey | director | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
From GuruFocus
By Business Wire Business Wire • 03-20-2023
By Business Wire Business Wire • 03-02-2023
By Business Wire • 11-21-2023
By Business Wire • 08-21-2023
By Business Wire • 07-18-2023
By Business Wire • 08-01-2023
By Business Wire Business Wire • 05-30-2023
By Business Wire Business Wire • 04-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.